Replies to post #81384 on Biotech Values

[wallstarb]

All I care about is the stock price after FDA approval - I think it'll do $100 - $200m annually - they think it does $600m - either way its at the minimal a triple from 4.60 area going into FDA approval decision then maybe $25 +/- the day after approval/partnership.

Time will tell. Either way it's the best risk/reward out there I see.

I guess we'll see!

[exwannabe]

Re: TSPT's market.

. The concept is that it is faster acting.
. This in turn allows a smaller dose.
. The smaller dose allows it to wear off faster
. Thus you can use it when you wake up at 2:00AM

There really is a market here. Nighttime waking insomnia is common.

On the downside, Zaleplon has similar properties. And Zolipmist (a nasal spray of zolpidem) could be used the same way as it is also fast acting, though it's label was based on full strength so you would have to semi-spray it. And many end up taking the standard (cheap) drug before going to sleep "just in case".

Regardless, I doubt any of this will matters. The stock will pop nicely and an FDA approval. There is no law that says you have to hold on then.

Hell, even GTCB was a 5 bagger, and that drug had nearly no market.